Thymosin beta-4
- Generic Name
- Thymosin beta-4
- Drug Type
- Biotech
- CAS Number
- 77642-24-1
- Unique Ingredient Identifier
- 549LM7U24W
- Background
Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
- First Posted Date
- 2011-07-04
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- ReGenTree, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT01387347
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
- Conditions
- END STAGE RENAL DISEASE
- Interventions
- Biological: MF59 adjuvanted H1N1 influenza monovalent vaccine
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2012-03-29
- Lead Sponsor
- sigma-tau i.f.r. S.p.A.
- Target Recruit Count
- 120
- Registration Number
- NCT01031966
- Locations
- 🇮🇹
Second Division of Nephrology and Dialysis - Padua Hospital, Padua, Italy
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00832091
- Locations
- 🇮🇹
Università degli Studi di Napoli - Federico II, Naples, Italy
🇮🇹Istituto Dermopatico dell'Immacolata (IDI), Rome, Italy
🇵🇱Klinika Chirurgii Naczyń i Angiologii, Lublin, Poland
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
- Conditions
- Myocardial IschemiaMyocardial Infarction
- Interventions
- Other: Placebo
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Registration Number
- NCT00743769
- Locations
- 🇺🇸
Healthcare Discoveries LLC, San Antonio, Texas, United States
Efficacy of Thymosin alpha1 for Severe Sepsis
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 366
- Registration Number
- NCT00711620
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- University Of Perugia
- Target Recruit Count
- 9
- Registration Number
- NCT00580450
- Locations
- 🇮🇹
Hematology Section, University of Perugia, Perugia, Italy
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2010-02-01
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00382174
- Locations
- 🇺🇸
Impact Clinical Trials, Beverly Hills, California, United States
🇺🇸Hines VAMC, Hines, Illinois, United States
🇺🇸Institute for Advanced Wound Care, Montgomery, Alabama, United States
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00311766
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.